United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$323.88 USD
-5.37 (-1.63%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $323.46 -0.42 (-0.13%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Brokerage Reports
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 521 - 540 ( 596 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
September and Remaining 2012 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2:12 Revenues And Earnings Beat (Again; 2012 Revenue Guidance Reconfirmed-Reiterate OUTPERFORM and $91Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Corporate Update: We Believe the Company Can Address Three Key Issues Causing Overhang on the Stock
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Movie Rental and Exhibitor Biweekly Newsletter-May 21 - June 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
ATS Preview: Data Presentations Support Clinical Profiles For Adcirca, Tyvaso, Remodulin, Oral Treprostinil and Beraprost
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1:12 Revenues and Earnings Beat, 2012 Revenue Guidance Reconfirmed, Reiterate UTPERFORM and $91 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Preview: We Believe Consensus for Product Sales Is Achievable
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
FDA Acceptance Of Oral Treprostinil NDA Solidifies The Timing For Potential Approval In Q
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L